EZH2 and lymphoma: Curiously, a recurrent mono-allelic activating mutation has been identified in EZH2 at tyrosine 641 in patients with lymphomas [68] while a series of apparent loss-of-function mutations have been found in patients with MDS and primary myelofibrosis [69–71].